Nontuberculous mycobacterial pulmonary infection in patients with cystic fibrosis: diagnosis and treatment.
The prevalence of nontuberculous mycobacteria (NTM) recovered from patients with cystic fibrosis (CF) appears to be increasing, probably related to improved surveillance and microbiological procedures and an increase in the life expectancy of patients with CF. The distinction between active lung infection and colonization is often difficult to assess in patients with CF because of the marked overlap in the clinical and radiological presentation of CF lung disease and lung disease caused by NTM infection. The possibility of active NTM lung infection should be considered in those patients with compatible radiographic changes and/or progressive deterioration in lung function who do not improve with specific antibiotic therapy and who have repeatedly positive sputum cultures and smears for NTM. Patients with repeatedly positive results of acid-fast smears are more likely to be infected than colonized. Pseudomonas overgrowth may confuse the results of sputum and bronchoalveolar lavage fluid cultures. Decontamination of respiratory samples from patients with CF with 5% oxalic acid results in improved bacteriological recovery of NTM. Skin tests are of limited value as a screening tool for NTM. Since the course of NTM lung infection is often slow, careful follow-up with repeated sputum cultures, chest radiographs and computed tomography (CT) scans may be needed. Treatment of NTM lung disease in patients with CF presents great difficulties because of abnormal gastrointestinal drug absorption and pharmacokinetics in this patient population. Treatment varies according to the mycobacterial species isolated. Long-term multidrug regimens including rifampin (rifampicin) and ethambutol are usually required. Monitoring serum drug levels is a useful indicator of correct dosage in order to prevent adverse effects due to potential drug interactions and altered pharmacokinetics in patients with CF.
Máiz-Carro
Luis
L
Department of Pulmonology (Cystic Fibrosis Unit), Hospital Ramón y Cajal, Madrid, Spain. lmaiz@hrc.insalud.es
Navas-Elorza
Enrique
E
D000995:Antitubercular Agents / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology*; D003937:Diagnosis, Differential; D006801:Humans; D015994:Incidence; D009164:Mycobacterium Infections / Q000175:diagnosis* / Q000188:drug therapy*
D000995:Antitubercular Agents